U.S., EUROPE, AND CHINA MYELODYSPLASTIC SYNDROME (MDS) TREATMENT MARKE ANALYSIS

Rising public awareness about myelodysplastic syndromes (MDS) and its early diagnosis and availability of new treatment options for MDS are expected to drive growth of the market over the forecast period. Moreover, early diagnosis of MDS is important because it significantly increases the quality of life in patients by early treatment, it also reduces the chances of recurrent blood transfusion and in more severe cases, as in 30% of the time, it can prohibit the evolution of the MDS disease into leukemia. Government organizations and drug manufacturing companies are focusing on spreading awareness about MDS by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American (Headquartered in Montevideo, Uruguay and with presence in 10 countries throughout the region) biopharmaceutical company conducted campaign to honor Myelodysplastic Syndrome World Awareness Day, which is celebrated on October 25. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about disease throughout the October month.   

The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market is estimated to be valued at US$ 2,042.6 Mn in 2020 and is expected to reach US$ 3,404.1 Mn by 2027, exhibiting a CAGR of 7.6% over the forecast period (2020-2027).

Figure 1. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2016-2027

To learn more about this report, request a free sample copy

The growing effort to introduce highly effective therapies for various MDS types is expected to drive the market growth over the forecast period.  

The rising efforts made by pharmaceutical companies to introduce highly effective therapies for MDS is a major factor that is expected to drive growth of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market over the forecast period. Moreover, increasing knowledge regarding the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS are supporting the market growth. Key pharmaceutical organizations in the U.S, Europe, and China myelodysplastic syndrome (MDS) treatment market such as Celgene are focusing on research and development (R&D) of MDS specific drugs and several of their drugs are showing potential in the clinical trials. For instance, in July 2018, Celgene (a part of Bristol Myers Squibb) and Acceleron collaborated and announced that luspatercept which is a medication used in the management and treatment of anemia in myelodysplastic syndromes, achieved all primary and key secondary endpoints in the phase III MEDALIST and BELIEVE trials in patients with low-to-intermediate risk myelodysplastic syndrome (MDS) and transfusion-dependent beta thalassemia, respectively.

Figure 2. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Share (%), by Drugs, 2020

To learn more about this report, request a free sample copy

U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products, and affected growth of the Myelodysplastic Syndrome (MDS) treatment businesses of various companies across the U.S, Europe, and China, as COVID 19 pandemic has led to unprecedented lockdown in several countries, globally. This lockdown has resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the products. Thus, COVID-19 pandemic has affected the economy by directly affecting the production and demand, by creating disruptions in distribution channels and also by its financial impact on firms and financial markets. For instance, according to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in over 100 million infected individuals worldwide and 25.6 million individuals in the U.S., 89,272 individuals in the China as of January 28, 2021. Thus, the impact of coronavirus (COVID-19) pandemic is expected to limit growth of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market during the forecast period.

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market: Restraint

Increased complexity of MDS disease may lead to death due to infection caused from low blood cell counts or after the disease becomes acute myeloid leukemia (AML). About a third of patients with MDS develop AML. This generates major hurdle in the development of effective MDS treatment. MDS represents several different conditions, as it is not just a single disease, but it is grouped together by several clinical characteristics. For instance, according to the data published in the Hematology journal of American Society of Hematology Education Program in December 2017, the type and complexity of hematopoietic dysfunction in MDS are highly variable and the kinetics of disease progression are difficult to predict. Moreover, genetic characteristics of MDS are powerfully associated with clinical phenotype. An enhanced understanding of the regulatory logic of MDS genetics may stimulate refined and biologically based diagnostic and monitoring schemes that may be integrated into clinical practice.

Key Players

Major players operating in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.